APLS
Apellis Pharmaceuticals Inc
NASDAQ: APLS · HEALTHCARE · BIOTECHNOLOGY
$40.95
-0.10% today
Updated 2026-04-29
Market cap
$5.24B
P/E ratio
227.50
P/S ratio
5.22x
EPS (TTM)
$0.18
Dividend yield
—
52W range
$16 – $41
Volume
5.4M
Apellis Pharmaceuticals Inc (APLS) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
5 of 8
Last 8 quarters
Avg EPS surprise
-5.5%
Last 4 quarters
Revenue YoY growth
-5.9%
Most recent quarter
EPS YoY growth
-62.1%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
-2.6%
Last 3 reports
Positive reaction rate
33%
1 of 3 quarters
Largest single-day move
-28.6%
2025-10-30
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-03-04 | $-0.47 | -24.0% | $20.16 | $20.15 | -0.0% |
| 2025-10-30 | $1.67 | +7.7% | $30.05 | $21.47 | -28.6% |
| 2025-07-31 | $-0.33 | +31.2% | $19.00 | $22.95 | +20.8% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | $-0.38 | $-0.47 | -24.0% | $199.91M | -5.9% |
| 2025-09-30 | $1.55 | $1.67 | +7.7% | $458.58M | +133.0% |
| 2025-06-30 | $-0.48 | $-0.33 | +31.2% | $178.49M | -10.6% |
| 2025-03-31 | $-0.54 | $-0.74 | -37.0% | $166.80M | -3.2% |
| 2024-12-31 | $-0.40 | $-0.29 | +27.8% | $212.53M | +45.2% |
| 2024-09-30 | $-0.30 | $-0.46 | -54.1% | $196.83M | +78.3% |
| 2024-06-30 | $-0.32 | $-0.28 | +12.5% | $199.69M | +110.3% |
| 2024-03-31 | $-0.47 | $-0.42 | +10.6% | $172.32M | — |
| 2023-12-31 | $-0.69 | $-0.73 | -5.8% | $146.38M | — |
| 2023-09-30 | $-0.86 | $-1.17 | -36.0% | $110.40M | — |
| 2023-06-30 | $-1.32 | $-1.02 | +22.7% | $94.97M | — |
Frequently asked questions
Has Apellis Pharmaceuticals Inc beaten earnings estimates?
Apellis Pharmaceuticals Inc has beaten Wall Street EPS estimates in 5 of its last 8 quarterly reports, with an average EPS surprise of -5.5% over the last 4 quarters.
How does APLS stock react to earnings?
APLS stock has moved an average of -2.6% in the trading day following earnings over its last 3 reports, with positive reactions in 33% of those quarters.
What is Apellis Pharmaceuticals Inc's revenue growth rate?
Apellis Pharmaceuticals Inc reported year-over-year revenue growth of -5.9% in its most recent quarter, with EPS growing -62.1% year-over-year.